Efficient Palladium-catalyzed Amination and Alkylation of 3-Iodo-6-arylpyridazines

Isabelle Parrot; Guillaume Ritter; Camille G. Wermuth; Marcel Hibert

doi:10.1055/s-2002-32595

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000083.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Synlett 2002(7): 1123-1127
DOI: 10.1055/s-2002-32595

LETTER

Efficient Palladium-catalyzed Amination and Alkylation of 3-Iodo-6-arylpyridazines

Isabelle Parrot, Guillaume Ritter, Camille G. Wermuth, Marcel Hibert*
Laboratoire de Pharmacochimie de la Communication Cellulaire, UMR 7081 CNRS/ULP, Université Louis Pasteur, Faculté de Pharmacie, 74 route du Rhin, 67401 Illkirch Cedex, France
Fax: +33(390)244310; e-Mail: mhibert@pharma.u-strasbg.fr;

Further Information

Publication History

Received 20 April 2002
Publication Date:
07 February 2007 (online)

Abstract
Full Text
References

Permissions and Reprints All articles of this category

Abstract

A simple and efficient amination and alkylation of 3-iodo-6-arylpyridazines has been performed using palladium-catalyzed cross coupling reaction. This new route allows access to a wide-ranging series of pharmacologically useful pyridazine derivatives.

Key words

amination - palladium - catalysis - pyridazine

References

1 Contreras JM. Parrot I. Sippl W. Rival Y. Wermuth CG. J. Med. Chem. 2001, 44: 2707

Crossref Google Scholar
2 Wermuth CG. J. Heterocycl. Chem. 1998, 35: 1091

Google Scholar
3 Wermuth CG. Contreras JM. Pinto J. Guilbaud P. Rival Y. Bourguignon JJ. Acta Pharm. Hung. 1996, S3

Google Scholar
4 Contreras JM. Rival YM. Chayer S. Bourguignon JJ. Wermuth CG. J. Med. Chem. 1999, 42: 730

Crossref Google Scholar
5 Negwer M. In Organic-Chemical Drugs and their Synonyms (An International Survey) 7th ed.: Akademie Verlag; Berlin: 1994.

Google Scholar
6 Parrot I. Rival Y. Wermuth CG. Synthesis 1999, 1163

Article in Thieme Connect Google Scholar
7 Aldous DJ. Bower S. Moorcroft N. Todd M. Synlett 2001, 150

Google Scholar
8 Toussaint D. Suffert J. Wermuth CG. Acta Chim. Sloven. 1994, 41: 253

Google Scholar
9 Maes BUW. Lemiere GLF. Dommisse R. Augustyns K. Haemer A. Tetrahedron 2000, 56: 1777

Crossref Google Scholar
10 Turck A. Plé N. Mojovic L. Quéguiner G. Bull. Soc. Chem. Fr. 1993, 130: 488

Google Scholar
11 Sosabowski M. Powell P. J. Chem. Res., Synop. 1995, 10: 402

Google Scholar
12 Draper TL. Bailey TR. J. Org. Chem. 1995, 60: 748

Google Scholar
13 Guery S. Parrot I. Rival Y. Wermuth CG. Tetrahedron Lett. 2001, 42: 2115

Crossref Google Scholar
14 Toussaint D. Suffert J. Wermuth CG. Heterocycles 1994, 38: 1273

Google Scholar
15 Yang B. Buchwald S. J. of Organomet. Chem. 1999, 576: 125

Crossref Google Scholar
16 Wolfe JP. Wagaw S. Marcoux J.-F. Buchwald SL. Acc. Chem. Res. 1998, 31: 805

Crossref Google Scholar
17 Hartwig J. Synlett 1996, 329

Google Scholar
18 Miyaura N. Ishiyama T. Sasaki H. Ishikawa M. Satoh M. Suzuki A. J. Am. Chem. Soc. 1989, 111: 314

Google Scholar
19 Sotelo E. Ravina E. Synlett 2002, 223

Article in Thieme Connect Google Scholar
20 Beletskaya IP. Bessmertnykh AG. Guilard R. Tetrahedron Lett. 1999, 40: 6393

Crossref Google Scholar

21

General Procedure for Amination. Method A: A mixture of 3-iodo-6-arylpyridazine 1 (X = I) (1 equiv), amine 2 (2.4 equiv), and sodium tert-butoxide (1.25 equiv) in dioxane was flushed with argon for 30 min under magnetic stirring. Then, PdCl₂(dppf) (0.05 equiv) and dppf (0.05 equiv) were added and the mixture was heated at 80 °C for 6 h. The dioxane was removed under reduced pressure and the residue was diluted with water, and extracted with EtOAc. The organic layer was washed with brine and concentrated under reduced pressure to give a crude product, which was purified by HPLC.
Method B: The procedure is the same as in Method A except for the amounts of 3-iodo-6-arylpyridazine 1 (2 equiv), and amine 2 (1 equiv). Method C: The procedure is the same as in Method A except for the work up. The dioxane was removed under reduced pressure, the residue diluted with water, and extracted with EtOAc. The organic layer was washed with brine and concentrated under reduced pressure to give a crude product which was dissolved in EtOAc, without further purification. Gaseous HCl was bubbled into the solution for 2 min, and the mixture was stirred at r.t. for 1 h. The chlorhydrate was then filtered and washed with ether.

22

General Procedure for Alkylation: In a first step a solution of trialkylborane was prepared. To a solution of 9-borabicyclo[3.3.1]borane 0.5 M in THF (2 equiv) under argon was added dropwise a solution of vinyl 4 (1 equiv) in THF. The mixture was stirred at r.t. for 4 h, and heated at reflux for 1 h.
The 3-iodo-6-arylpyridazine 1 (1 equiv) was added to a solution of K₃PO₄ (3 equiv) dissolved in a small amount of DMF:H₂O 6:2. This mixture was flushed with argon for 30 min under magnetic stirring. Then, PdCl₂(dppf) (0.05 equiv), dppf (0.05 equiv), and the trialkylborane solution were added and the mixture was heated at 70 °C for 6 h. The solvent was removed under reduced pressure, the residue diluted with water, and extracted with EtOAc. The organic layer was washed with brine and concentrated under reduced pressure to give a crude product which was purified by HPLC. [23]

23

All compounds were isolated and collected by a reverse phase high pressure liquid chromatography column (Gilson C18), equilibrated with 90% A (0.1% trifluoroacetic acid in H₂O) 1% solvent B (0.1% trifluoroacetic acid in MeOH) and eluting at 1 mL/min using a 10-95% gradient of solvent B in 50 min.
Selected data for: Benzyl-(4-ethyl-6-phenyl-pyridazin-3-yl)-amine(3b): colorless oil, ¹H NMR (CDCl₃, 200 MHz): δ = 1.36 (t, 3 H, J = 7.2 Hz), 2.68 (m, 2 H), 4.76 (s, 2 H), 6.95 (s, 1 H, H_-NH-), 7.26-7.64 (m, 8 H), 7.80 (s, 1 H), 7.80 (m, 2 H); ¹³C NMR (CDCl₃, 75 MHz): δ = 11.7, 22.6, 46.2, 123.5, 126.3, 127.6, 128.2, 128.9, 129.2, 131.7, 135.8, 138.3, 151.4, 155.6; SM (ES): m/z (%) = 290.18(100) [M + H]⁺.
Benzyl-[6-(2-methoxy-phenyl)-5-methyl-pyridazin-3-yl]-amine(3c): white solid, ¹H NMR (CD₃OD, 200 MHz): δ = 2.36 (s, 3 H), 4.00 (s, 3 H), 4.80 (s, 2 H), 5.25 (s, 1 H), 7.28-7.73 (m, 10 H); ¹³C NMR (CD₃OD, 75 MHz): δ = 22.4, 49.8, 59.3, 115.5, 125.2, 125.5, 128.4, 131.9, 132.2, 133.0, 134.5, 136.4, 136.7, 139.5, 150.7, 154.1, 158.9; SM (ES: m/z (%) = 306.19(100) [M + H]⁺, 328.05(15) [M + Na]⁺.
Benzyl-bis-[6-(2-methoxy-phenyl)-5-methyl-pyridazin-3-yl]-amine(3d): white solid, ¹H NMR (CDCl₃, 200 MHz): δ = 2.20 (s, 6 H), 3.81 (s, 6 H), 5.65 (s, 2 H), 6.99-7.10 (m, 2 H), 7.32-7.45 (m, 11 H), 7.62 (s, 2 H); ¹³C NMR (CDCl₃, 75 MHz): δ = 19.4, 52.5, 55.8, 111.3, 114.8, 121.4, 123.8, 127.7, 129.1, 131.5, 133.1, 139.8, 148.2, 149.1, 158.4; SM (ES): m/z (%) = 504.30(100) [M + H]⁺. N -1-Ethyl- N -1-[6-(2-methoxy-phenyl)-5-methyl-pyri-dazin-3-yl]-ethane-1,2-diamine(3e): colorless oil, ¹H NMR (CDCl₃, 200 MHz): δ = 1.27 (t, 3 H, J = 7.0 Hz), 2.15 (s, 3 H), 2.98 (m, 2 H), 3.30 (m, 2 H), 3.79 (s, 3 H), 3.98 (m, 2 H), 6.97-7.21 (m, 3 H), 7.29-7.52 (m, 2 H); ¹³C NMR (CDCl₃, 75 MHz): δ = 11.4, 19.4, 39.3, 44.2, 45.8, 55.8, 110.1, 111.4, 121.5, 130.7, 132.4, 136.1, 150.6, 154.8, 158.9; SM (ES): m/z (%) = 287.22(100) [M + H]⁺.
N ′-Ethyl- N -[6-(2-methoxy-phenyl)-5-methyl-pyridazin-3-yl]- N -[6-(2-methoxy-phenyl)-pyridazin-3-yl]-ethane-1,2-diamine(3f): colorless oil, ¹H NMR (CDCl₃, 200 MHz): δ = 1.34 (t, 3 H, J = 7.1 Hz), 2.35 (s, 6 H), 3.14 (m, 2 H), 3.54 (m, 2 H), 3.77 (t, 2 H, J = 7.4 Hz), 3.86 (s, 6 H), 4.83 (s, 1 H), 7.07-7.11 (m, 4 H), 7.38 (m, 2 H), 7.60 (m, 2 H), 8.04 (s, 2 H); ¹³C NMR (CDCl₃, 75 MHz): δ = 10.8, 18.8, 44.6, 46.3, 46.7, 55.5, 111.2, 111.4, 121.3, 124.8, 129.7, 130.6, 133.3, 146.2, 155.7, 156.9; SM (ES): m/z (%) = 485.32(100) [M + H]⁺.
N -1-Ethyl- N -1-[6-(2-methoxy-phenyl)-5-methyl-pyri-dazin-3-yl]-ethane-1,2-diamine(3g): pale yellow oil,
¹H NMR (CDCl₃, 200 MHz): δ = 1.13 (t, 3 H, J = 7.1 Hz), 2.05 (s, 3 H), 2.71 (t, 2 H, J = 6.3 Hz), 2.94 (m, 2 H), 3.56 (t, 2 H, J = 6.4 Hz), 3.76 (s, 3 H), 5.28 (s, 2 H), 6.54 (s, 1 H), 6.94-7.07 (m, 2 H), 7.32-7.39 (m, 2 H); ¹³C NMR (CDCl₃, 75 MHz): δ = 14.5, 19.1, 41.2, 44.1, 48.6, 55.8, 111.1, 114.4, 121.2, 125.2, 130.5, 131.5, 137.0, 148.3, 154.4, 158.3; SM (ES): m/z (%) = 387.26(100) [M + H]⁺.
3-[2-(1-Benzylpiperidin-4-yl)ethylamino]-5-methyl-6-(2-methoxyphenyl)pyridazine(3h): pale orange oil, ¹H NMR (CDCl₃, 200 MHz): δ = 1.28-1.43 (m, 3 H), 1.56-1.63 (m, 2 H), 1.69 (d, 2 H, J = 11.7 Hz), 1.93 (t, 2 H, J = 11.3 Hz), 2.22 (s, 3 H), 2.87 (d, 2 H, J = 11.7 Hz), 3.38-3.45 (m, 2 H), 3.48 (s, 2 H), 3.77 (s, 3 H), 5.15 (t, 1 H, J = 5.6 Hz), 6.96-7.19 (m, 4 H), 7.36-7.48 (m, 6 H); ¹³C NMR (CDCl₃, 75 MHz): δ = 19.7, 28.6, 30.6, 33.7, 39.0, 52.3, 55.5, 60.9, 111.0, 121.3, 129.3, 130.1, 130.6, 131.2, 131.8, 136.3, 139.6, 156.7, 162.2, 162.7; SM (ES): m/z (%) = 417.29(100) [M + H]⁺.
Ethyl 11-(4-Ethyl-6-phenyl-pyridazin-3-yl)-undec-anoate(3i): colorless oil, ¹H NMR (CDCl₃, 75 MHz): δ = 1.22-1.61 (m, 22 H), 2.28 (t, 2 H, J = 7.4 Hz), 2.73 (m, 2 H), 3.00 (t, 2 H, J = 7.8 Hz), 4.11 (m, 2 H), 7.47-7.50 (m, 3 H), 7.59 (s, 1 H), 8.07 (m, 2 H); ¹³C NMR (CDCl₃, 75 MHz):
δ = 13.6, 14.6, 22.4, 23.1, 24.8, 25.3, 26.8, 27.8, 29.4, 29.5, 29.6, 29.8, 30.0, 32.6, 33.1, 34.8, 35.1, 60.5, 123.1, 127.3, 129.2, 129.9, 135.3, 137.8, 151.7, 174.0; SM (ES): m/z (%) = 397.34(100) [M + H]⁺. tert -Butyl {3-[6-(2-Methoxy-phenyl)-5-methyl-pyri-dazin-3-yl]-propyl}-carbamate(3j): pale yellow oil,
¹H NMR (CDCl₃, 200 MHz): δ = 1.43 (s, 9 H), 2.06-2.21 (m, 4 H), 2.40 (s, 3 H), 3.23 (t, 2 H, J = 6.6 Hz), 3.80 (s, 3 H), 7.02-7.42 (m, 4 H), 7.80 (s, 1 H); ¹³C NMR (CDCl₃, 75 MHz): δ = 19.6, 28.7, 29.6, 30.6, 39.8, 55.9, 79.3, 111.3, 121.4, 130.8, 131.0, 131.5, 132.7, 139.0, 155.2, 156.2, 157.7, 158.5; SM (ES): m/z (%) = 358.25(100) [M + H]⁺.